SecBot SecBot
6-K ·Filed Aug 28, 2026

BNTX

BioNTech SE
BEARISH
Impact 6/10
Horizondays Processed2mo ago SEC0001776985-26-000061
Notable filing: 6-K
Actionable Insight ▼ Bearish

The termination removes a key catalyst for BioNTech's mRNA monotherapy thesis in CRC, an immunologically cold tumor. Monitor for full data analysis and any read-through to the ongoing PDAC combination trial. The stock may see pressure from this de-risking failure, but the broader oncology pipeline and COVID franchise provide a buffer.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$102.08
T+0 close · Aug 28, 2026 · via day close
Latest settled
−3.48%
T+20 · $98.52 · next T+60 in 6d
Vs SPY
−3.99%
α at T+20
Latest observation
−11.66%
T+54 · FF3 residual α
  1. T+0 · Aug 28 $102.08entry
  2. T+1 · 3mo ago −0.46%α −0.16% · $101.61
  3. T+5 · 2mo ago +1.65%α +1.54% · $103.76
  4. T+20 · 7w ago −3.48%α −3.99% · $98.52
  5. T+55 · todayOpen
  6. T+60 · in 6d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy in resected colorectal cancer after a DSMB recommendation citing a numerical overall survival imbalance and futility. The decision follows a prior futility boundary crossing in October 2025. The separate Phase 2 PDAC trial (IMcode003) combining autogene cevumeran with checkpoint inhibition continues unaffected. This is a meaningful pipeline setback for BioNTech's mRNA cancer immunotherapy platform in a key indication, though the company has multiple other oncology programs.

Key Facts

  • BioNTech terminated Phase 2 trial BNT122-01 of autogene cevumeran in ctDNA-positive resected Stage II/III colorectal cancer.
  • DSMB recommended termination after identifying a numerical imbalance in overall survival between treatment arms; no new safety signals.
  • Futility boundary was crossed in October 2025 but DSMB deemed data immature at that time.
  • The separate Phase 2 PDAC trial (IMcode003, NCT05968326) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy continues as planned.
  • Autogene cevumeran is jointly developed with Genentech (Roche).

Financial Impact

Pipeline setback in colorectal cancer; no financial figures disclosed in filing. BioNTech has a $28B market cap with multiple other oncology programs.

pipeline valueR&D outlook

Risk Factors

  • Negative overall survival signal may raise questions about mRNA monotherapy efficacy in cold tumors.
  • Potential for further pipeline delays or reprioritization if other monotherapy trials face similar challenges.
  • Partner Genentech may reassess commitment to the mRNA cancer immunotherapy collaboration.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000061
Document: 0001776985-26-000061-index-headers.html0001776985-26-000061
Document: 0001776985-26-000061-index.html0001776985-26-000061
Document: 0001776985-26-000061.txt0001776985-26-000061

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026